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Original investigation Postprandial endothelial dysfunction in subjects 
with new-onset type 2 diabetes: an acarbose and 
nateglinide comparative study
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Abstract
Background: Postprandial hyperglycemia is believed to affect vascular endothelial function. The aim of our study was 
to compare the effects of acarbose and nateglinide on postprandial endothelial dysfunction.
Methods: We recruited a total of 30 patients with newly diagnosed type 2 diabetes (19 men and 11 women, age 67.8 
± 7.3 years). Patients were randomly assigned to 3 groups receiving either 300 mg/day acarbose, 270 mg/day 
nateglinide, or no medication. A cookie test (consisting of 75 g carbohydrate, 25 g butter fat, and 7 g protein for a total 
of 553 kcal) was performed as dietary tolerance testing. During the cookie test, glucose and insulin levels were 
determined at 0, 30, 60, and 120 min after load. In addition, endothelial function was assessed by % flow-mediated 
dilation (FMD) of the brachial artery at 0 and 120 min after cookie load.
Results: Postprandial glucose and insulin levels were similar in the 3 groups. Postprandial endothelial dysfunction was 
similar in the 3 groups before treatment. After 12 weeks of intervention, postprandial FMD was significantly improved 
in the acarbose group compared with the control group (6.8 ± 1.3% vs 5.2 ± 1.1%, p = 0.0022). Area under the curve 
(AUC) for insulin response was significantly increased in the nateglinide and control groups; however, no significant 
change was observed in the acarbose group.
Conclusions: Our results suggest that acarbose improves postprandial endothelial function by improvement of 
postprandial hyperglycemia, independent of postprandial hyperinsulinemia. Acarbose may thus have more beneficial 
effects on postprandial endothelial function in patients with type 2 diabetes than nateglinide.
Introduction
Epidemiological studies have revealed that postprandial
hyperglycemia is a more powerful predictor of future car-
diovascular events than fasting hyperglycemia [1,2].
Endothelial dysfunction is not only an early marker of
atherosclerosis but is also strongly associated with risk of
future cardiovascular events [3]. Endothelial dysfunction
is associated with cardiovascular risk factors such as
smoking [4], dyslipidemia [5,6], hypertension [7,8], obe-
sity [9], type 2 diabetes [10], and postprandial hyperglyce-
mia [11]. Postprandial endothelial dysfunction,
postprandial hyperglycemia and cardiovascular events
are all strongly associated with one another [12,13].
Since the postprandial state occurs during most of the
daytime, interventions that aim to reduce postprandial
endothelial dysfunction are essential for the prevention of
cardiovascular events. Currently, there is no gold stan-
dard for treatment of postprandial endothelial dysfunc-
tion. However, several pharmacological therapeutic
approaches have been suggested. Potential agents to tar-
get postprandial hyperglycemia in patients with type 2
diabetes include α-glucosidase inhibitors and glinide
drugs. Acarbose, an α-glucosidase inhibitor, reduces or
delays carbohydrate digestion by competitive and dose-
dependent inhibition of α-glucosidase enzymes located in
the brush border of the small intestine. The α-glucosidase
enzymes metabolize non-absorbable oligosaccharides
into absorbable monosaccharides. Thus, acarbose signifi-
cantly reduces the postprandial rise in glucose without
increasing circulating insulin levels. Recent clinical trials
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have shown that acarbose treatment can prevent cardio-
vascular complications not only in patients with type 2
diabetes but also in those with impaired glucose tolerance
[14,15]. Thus, acarbose may be an effective therapeutic
modality in patients with postprandial hyperglycemia.
In contrast, the D-phenylalanine derivative nateglinide
is an insulinotropic agent with rapid effects and a short
duration of action which acts as an insulin secretagogue
in the treatment of type 2 diabetes, and which is reported
to lower the 24-h glucose profile without increasing total
insulin secretion [16,17].
Although the effects of solo administration of acarbose
or nateglinide on the improvement of postpandial
endothelial function have been assessed [18-20], there are
no comparative studies looking at both agents. In this
open-label prospective study, we compared the effects of
acarbose and nateglinide on postprandial endothelial
function in newly diagnosed type 2 diabetes.
Methods
Study design
We recruited a total of 30 patients with type 2 diabetes
(19 men and 11 women, age 67.8 ± 7.3 years, HbA1c 6.0 ±
0.5%), who were diagnosed according to the WHO crite-
ria [21]. Subjects were advised to consume their normal
diet during the entire period of the study. Smokers, sub-
jects who had any history of cardiovascular disease, and
subjects taking lipid lowering agents or supplemental
vitamins were excluded. All of the study subjects were
randomly assigned to receive one of the following treat-
ments for 12 weeks: 300 mg/d acarbose (n = 10), 270 mg/
d nateglinide (n = 10) or no medication (n = 10) as a con-
trol group. At the initiation of treatment and at the end of
12 weeks of treatment, cookie test was performed as a
dietary tolerance test. Written informed consent was
obtained from all subjects, with local ethics committee
approval.
Cookie test
The cookie test was performed after overnight fasting,
using previously described methods [22], at baseline
before treatment and 12 weeks after treatment. Subjects
were instructed to refrain from smoking and drinking
coffee or alcoholic beverages beginning the night before
the study. The cookie consisted of 75 g carbohydrate (85%
flour starch, 15% maltose), 25 g butter and 7 g protein for
a total of 553 kcal. (ABILIT Corp, Osaka, Japan). Subjects
were encouraged to ingest the cookie with water within
15 min. Time measurement was started at the time when
half of the cookie had been ingested. Blood samples were
obtained during the fasting state before cookie ingestion,
and at 30 min, 60 min and 120 min after the cookie load.
Plasma glucose and insulin levels were determined at
e a c h  t i m e  p o i n t .  V a s c u l a r  e n d o t h e l i a l  f u n c t i o n  w a s
assessed in the fasting state before cookie ingestion and
120 min after the cookie load as the postprandial state.
Biochemical measurement
Plasma glucose levels were measured using the glucose-
oxidase method, and plasma insulin levels were measured
by immunoassay). Glycohemoglobin (Hb) A1c was mea-
sured by high-performance liquid chromatography. From
the fasting glucose and insulin levels, insulin resistance
was assessed using homeostasis model assessment
(HOMA-IR) according to the following formula: fasting
plasma glucose (mg/dl)×fasting plasma insulin (μU/ml)/
405 [23].
Using the fasting blood samples taken before cookie
ingestion, the levels of total cholesterol (TC) and triglyc-
erides (TG) were measured enzymatically. High-density
lipoprotein cholesterol (HDL-C) was estimated after pre-
cipitation of apolipoprotein B with phosphotungstate/
magnesium. The low-density lipoprotein cholesterol
(LDL-C) level was calculated according to the Friedewald
formula [24].
Assessment of vascular endothelial function
Vascular endothelial function was assessed by measuring
flow-mediated dilation (FMD) of the brachial artery using
established and validated methods [25,26]. A high-resolu-
tion ultrasound system was equipped with vascular soft-
ware for 2-dimensional imaging with a pulse Doppler
flow velocimeter, and a linear array transducer probe with
a frequency of 7.5 MHz was used (SSA-550A, Toshiba,
Japan). The study was performed in the morning under
fasting conditions, after resting quietly for at least 10
minutes in a light- and temperature-controlled room.
After baseline measurements of the brachial artery diam-
eter, a blood pressure cuff was inflated to 200 mm Hg
over the proximal portion of the right forearm for 5 min-
utes. FMD was determined 1 minute after release of the
cuff. The FMD is expressed as the maximum change in
diameter after cuff release normalized to the baseline
diameter (% of baseline diameter). Response to 150 μg of
nitroglycerine was used for assessment of endothelium-
independent nitroglycerin-mediated dilation (%NMD) of
the brachial artery.
Statistical Analysis
Results are expressed as means ± SD. The Kolmogorov-
Smirnov algorithm was used to determine whether each
variable had a normal distribution. Comparisons of base-
line data among the three groups were performed with
one-way analysis of variance (ANOVA) followed by a
post-hoc Fisher's PLSD test. The paired Student's t test
was used for comparison of the various parameters
before and after treatment. Changes in measured vari-
ables during the tests were assessed by 2-way ANOVA
with repeated measures. If differences reached statisticalKato et al. Cardiovascular Diabetology 2010, 9:12
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significance, post hoc analysis with a 2-tailed paired t test
was used to assess differences at individual time points in
the study, with the Bonferroni correction used for multi-
ple comparisons. The area under the curve (AUC) was
calculated by the trapezoidal method. Statistical signifi-
cance was defined as P < 0.05. All statistical analyses were
performed using SPSS 11.0.1J for Windows (SPSS Inc.)
Results
Characteristics of study subjects before and after treatment
Baseline characteristics before treatment including age,
sex, body mass index (BMI), lipid parameters, HbA1c,
glucose, insulin, HOMA-IR, systolic and diastolic blood
pressure, and heart rate were similar among the 3 groups.
Characteristics of the study subjects after 12 weeks of
treatment were also similar among the 3 groups (Table 1).
Glucose and insulin levels during cookie test
Blood pressure and heart rate did not change during the
cookie test (from baseline values to 120 min after cookie
load) at baseline before treatment (143.5 ± 28.5/89.1 ±
19.2 to 142.5 ± 25.4/86.9 ± 19.6 mmHg, 68.8 ± 9.8 to 68.1
± 9.4/min in the control group, 141.1 ± 26.1/88.1 ± 23.1
to 142.6 ± 26.4/86.5 ± 26.5 mmHg, 69.2 ± 11.1 to 67.9 ±
11.0 in the acarbose group and 141.3 ± 28.5/88.3 ± 11.9 to
142.9 ± 24.2/89.4 ± 21.5 mmHg, 68.2 ± 8.9 to 67.1 ± 9.6/
min in the nateglinide group) and after 12 weeks of treat-
ment (145.5 ± 38.2/89.3 ± 11.9 to 145.8 ± 34.2/87.5 ± 16.1
mmHg, 68.8 ± 8.9 to 68.1 ± 9.4/min in the control group,
142.6 ± 19.1/83.1 ± 38.9 to 142.9 ± 28.9/84.6 ± 32.6
mmHg, 62.9 ± 11.2 to 63.9 ± 11.1 in the acarbose group
and 143.8 ± 23.5/68.9 ± 8.2 to 142.2 ± 22.9/89.2 ± 26.7
mmHg, 68.9 ± 8.2 to 67.1 ± 9.9/min in the nateglinide
group).
Plasma glucose levels were significantly decreased at 30
min during the cookie test after 12 weeks of acarbose
treatment (from 165.9 ± 29.1 mg/dl to 137.0 ± 26.2, p =
0.031). Plasma insulin levels were significantly increased
at 30 and 60 min after 12 weeks of nateglinide treatment
(from 17.8 ± 12.2 to 40.5 ± 9.4 uU/ml, p = 0.00019, and
from 28.6 ± 16.7 to 47.6 ± 14.6 uU/ml, p = 0.0078, respec-
tively) (Fig. 1). The AUCs for glucose and insulin levels
during the cookie test were calculated before and after
treatment. Before treatment, the AUC for glucose levels
was similar among the 3 groups (2041.8 ± 236.7 mg/dl×h
in the control group, 2234.3 ± 326.7 mg/dl×h in the acar-
bose group, 2209.0 ± 306.8 mg/dl×h in the nateglinide
group). After 12 weeks of treatment, the AUC for glucose
levels was significantly decreased in all 3 groups (p <
0.00001 in every group) without any intergroup differ-
ence (to 1420.4 ± 127.8 mg/dl×h in the control group, to
1354.1 ± 293.2 mg/dl×h in the acarbose group, and to
1389.9 ± 212.2 mg/dl×h in the nateglinide group). Before
treatment, the AUC for insulin levels before treatment
was also similar among the 3 groups (421.9 ± 185.3 uU/
ml×h in the control group, 464.4 ± 164.8 uU/ml×h in the
acarbose group, and 315.8 ± 153.5 uU/ml×h in the nat-
eglinide group). After 12 weeks of treatment, the AUC for
insulin levels was significantly increased in the control
and nateglinide groups (to 678.9 ± 196.3 uU/ml×h, p =
0.007, and to 915.1 ± 298.8 uU/ml×h, p < 0.00001, respec-
tively). However, it did not change in the acarbose group
(636.7 ± 275.8 uU/ml×h, p = 0.17).
Effects of acarbose or nateglinide on postprandial 
endothelial function
At baseline before treatment, the baseline brachial artery
diameter was similar among the control, acarbose and
nateglinide groups (4.1 ± 0.3, 4.1 ± 0.3 and 4.0 ± 0.3 mm,
respectively). Fasting FMD was also similar among the 3
groups. Postprandial FMD (120 min after cookie load)
was significantly lower than fasting FMD in each group
(4.2 ± 1.3 vs. 9.6 ± 2.7 in the control group, 4.5 ± 1.3 vs.
8.9 ± 2.2 in the acarbose group, and 4.4 ± 2.2 vs. 8.4 ±
3.1% in the nateglinide group, p < 0.001 for each).
After 12 weeks of treatment, fasting FMD did not
change significantly in any of the 3 groups (to 10.2 ± 2.1
in the control group, 8.3 ± 3.2 in the acarbose group and
8.6 ± 3.2% in the nateglinide group), compared to the
baseline before treatment. Postprandial FMD was lower
in each group after 12 weeks of treatment (5.2 ± 1.0 in the
control group, p < 0.001, 6.8 ± 1.3 in the acarbose group,
p < 0.05 and 5.6 ± 1.9% in the nateglinide group p = 0.05)
than fasting FMD. Postprandial FMD in the acarbose
group was significantly higher (p < 0.05) than that of the
control group (Fig. 2) after 12 weeks of treatment. The
percent postprandial decrease in FMD [(postprandial
FMD-fasting FMD)× 100/fasting FMD] was significantly
suppressed in the acarbose group after 12 weeks of treat-
ment compared to the control group (-1.5 ± 0.95 vs. -5.0
± 2.4%, p < 0.001) or to the nateglinide group (-3.2 ± 1.6%,
p < 0.05). The postprandial decrease in FMD in the nat-
eglinide group was also suppressed, compared to that in
the control group (p < 0.01) (Fig. 3).
Postprandial %NMD was similar to fasting %NMD in
each group. Postprandial and fasting %NMD were similar
among the 3 treatment groups at baseline before treat-
ment and also after 12 weeks of treatment.
Discussion
Our study has demonstrated that 12 weeks of treatment
with acarbose or nateglinide improved postprandial
endothelial dysfunction in newly diagnosed type 2 dia-
betic subjects and that acarbose was more effective than
nateglinide. To the best of our knowledge, this is the first
study to directly compare the effects of the α-glucosidase
inhibitor acarbose and the glinide drug nateglinide on
postprandial endothelial function.Kato et al. Cardiovascular Diabetology 2010, 9:12
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Postprandial endothelial dysfunction
It is known that endothelial dysfunction occurs postpran-
dially and that postprandial hyperglycemic spikes may
induce endothelial dysfunction. This phenomenon is
probably linked to reduced production and bioavailability
of nitric oxide (NO), since hyperglycemia-induced
endothelial dysfunction is counterbalanced by arginine
[26]. Kawano et al. [11] investigated endothelial function
during oral glucose tolerance testing (OGTT) using bra-
chial FMD in 3 groups of subjects with either normal glu-
cose tolerance, impaired glucose tolerance, or type 2
diabetes. At 60 min after a glucose load, FMD was signifi-
cantly reduced in all groups. They also found that FMD
was inversely correlated with plasma levels of thiobarbi-
turic acid reactive substances as well as plasma glucose
levels at 60 min after a glucose load. Their results suggest
that postprandial hyperglycemia rapidly impairs endothe-
lial function through an increase in hyperglycemia-
induced oxidative stress.
Cookie load and postprandial hyperglycemia
In most studies, postprandial endothelial dysfunction has
been evaluated using OGTT. However, normal meal
ingestion does not involve carbohydrate alone but also
includes includes fat and protein. Meal absorption is a
complex phenomenon in which postprandial hypertrig-
lyceridemia as well as postprandial hyperglycemia are
simultaneously present in the post-absorptive phase, par-
ticularly in patients with diabetes. Ceriello et al. have
demonstrated that there are independent and cumulative
effects of postprandial hypertriglyceridemia and post-
prandial hyperglycemia on endothelial function and have
pointed out that oxidative stress is a common mediator of
Table 1: Characteristics of study subjects before and after treatment
Control (n = 10) Acarbose (n = 10) Nateglinide (n = 10)
Baseline 12 weeks Baseline 12 weeks Baseline 12 weeks
Age (years) 68.0 ± 7.7 67.6 ± 6.2 67.8+/-8.6
Male gender 
(%)
5 (50) 7 (70) 7 (70)
BMI (kg/m2) 26.8 ± 3.2 26.1 ± 3.4 25.8 ± 2.5 25.3 ± 7.4 25.8 ± 3.3 25.5 ± 2.9
Total 
cholesterol 
(mg/dl)
213.2 ± 15.9 210.2 ± 23.2 201.8 ± 25.4 205.7 ± 38.1 206.0 ± 25.4 211.1 ± 29.6
Triglyceride 
(mg/dl)
132.4 ± 13.1 127.7 ± 17.1 116.1 ± 20.8 125.5 ± 34.7 121.7 ± 19.3 121.6 ± 22.3
HDL 
cholesterol 
(mg/dl)
53.8 ± 11.0 53.7 ± 9.5 56.2 ± 11.0 52.7 ± 14.4 54.4 ± 12.5 57.4 ± 13.2
LDL 
cholesterol 
(mg/dl)
135.0 ± 48.8 143.9 ± 52.7 141.6 ± 69.3 137.4 ± 77.3 149.4 ± 76.0 121.6 ± 22.3
HbA1c (%) 5.8 ± 0.6 5.6 ± 0.5 6.0 ± 0.3 5.9 ± 0.4 6.1 ± 0.6 5.8 ± 0.4
Fasting 
glucose 
(mg/dl)
110.7 ± 15.0 109.3 ± 12.0 109.6 ± 17.5 108.8 ± 15.7 119.6 ± 17.5 110.4 ± 11.1
Fasting insulin 
(μU/ml)
7.5 ± 2.9 7.2 ± 2.8 9.6 ± 5.6 10.6 ± 6.8 6.6 ± 4.1 6.5 ± 2.7
HOMA-IR 2.0 ± 0.7 1.9 ± 1.8 2.6 ± 1.6 2.8 ± 1.9 2.0 ± 1.6 1.8 ± 0.7
Systolic BP 
(mmHg)
143.5 ± 28.5 145.5 ± 38.2 141.1 ± 26.1 142.6 ± 19.1 141.3 ± 28.5 143.8 ± 23.5
Diastolic BP 
(mmHg)
89.1 ± 19.2 89.3 ± 11.9 88.1 ± 23.1 83.1 ± 38.9 88.3 ± 11.9 89.1 ± 23.8
Heart rate 
(beats/min)
68.8 ± 9.8 68.8 ± 8.9 69.2 ± 11.1 62.9 ± 11.2 68.2 ± 8.9 68.9 ± 8.2
Data are shown as mean ± SD. BMI, body mass index; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; HbA1c, glycohemoglobin 
A1c; HOMA-IR, insulin resistance by homeostasis model assessment; BP, blood pressure.Kato et al. Cardiovascular Diabetology 2010, 9:12
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both postprandial states [27]. Harano et al. [22] showed
that both hyperglycemia and hypertriglyceridemia occur
after a cookie load. Although we did not assess triglycer-
ide levels during the cookie test, postprandial endothelial
dysfunction in the present study may in part result from
postprandial hypertriglyceridemia in addition to post-
prandial hyperglycemia.
In our results, the effects of acarbose on improvement
of postprandial endothelial dysfunction were superior to
those of nateglinide, despite the fact that both agents sim-
ilarly reduced postprandial plasma glucose levels.
Although acarbose and nateglinide are both effective in
moderating postprandial hyperglycemia, their mecha-
nisms are quite different. Acarbose acts by competitively
inhibiting the α-glucosidases, a group of key enzymes
involved in the digestion of carbohydrates. Acarbose
reduces both postprandial hyperglycemia and hyperinsu-
linemia, and thereby may improve sensitivity to insulin
and alleviate stress on pancreatic β-cells. In contrast, nat-
eglinide, a glinide compound, selectively enhances early
meal-induced insulin secretion and thus improves meal-
time glucose control.
In our study, both acarbose and nateglinide similarly
inhibited postprandial hyperglycemia as assessed by AUC
for glucose levels. While nateglinide increased the AUC
for insulin, acarbose did not increase postprandial insulin
secretion. Therefore, acarbose may improve postprandial
endothelial function by inhibiting postprandial hypergly-
cemia without increasing postprandial insulin secretion,
while nateglinide may improve postprandial endothelial
function less significantly by inhibiting postprandial
hyperglycemia with an increase in postprandial insulin
secretion. Recently, Arcano et al. [28] reported that insu-
lin may cause endothelial dysfunction in humans.
Athough the mechanisms through which insulin might
impair endothelial function are not well clarified, the
Figure 1 Glucose and insulin levels at each time point during a cookie test in the control, acarbose and nateglinide groups. Plasma glucose 
and insulin levels were not changed at any time point in the controls after 12 weeks. Plasma glucose levels at 30 min during the cookie test were 
significantly decreased after 12 weeks of treatment with acarbose. Plasma insulin levels at 30 and 60 min were significantly increased after 12 weeks 
of nateglinide treatment.Kato et al. Cardiovascular Diabetology 2010, 9:12
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hyperinsulinemia-induced increase in oxidative stress
appears to be involved. Since vitamin C completely
reversed insulin-induced endothelial dysfunction without
affecting the vascular endothelium-independent
response, they speculated that oxidative stress was one of
the intermediate steps in insulin-induced endothelial dys-
function. Another recent study showed that insulin acti-
vates both the nitrergic and the endothelinergic systems
[29]. Endothelin-1 induces NAD(P)H oxidase expression
in human endothelial cells, with increased generation of
superoxide anions [30]. It is also known that exogenous
hyperinsulinemia activates NAD(P)H in the rat aortic
endothelium [31]. Thus, insulin may also cause endothe-
lial dysfunction through increased endothelin-1 availabil-
ity and through downstream effects on NAD(P)H oxidase
and superoxide anion production. Our results may pro-
vide evidence that both hyperglycemia and hyperinsu-
linemia cause endothelial dysfunction.
Shimabukuro et al. [19,20] have previously demon-
strated that a single administration of acarbose or nat -
eglinide improved postprandial endothelial dysfunction
in type 2 diabetes. However, they did not compare the
long-term effects of both agents on postprandial
endothelial function. A recent study by Major-Pedersen
et al. [32] showed that postprandial endothelial dysfunc-
tion could be prevented by a single administration of nat-
eglinide, but this effect was abolished after 12 weeks of
nateglinide treatment. They speculated that chronically
increased insulin secretion resulting from long-term nat-
eglinide treatment could counteract the initial beneficial
effects of reduced glucose excursion.
Clinical implications/conclusions
Acarbose improves postprandial endothelial dysfunction
in both the short-term (single dose) and in the long-term
administration. Our findings appear to partially support
the results of the STOP-NIDDM trial [14] and a meta-
analysis of several clinical studies [18].
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